Cullen Capital Management, LLC, operating as Schafer Cullen Capital Management, Inc., released its third-quarter investor letter. The US equity market saw gains, with the S&P 500 returning 8.1% and the Russell 1000 Value surging 5.3%. The value equity strategy returned 6.9% gross and 6.8% net in the quarter, outperforming the Russell 1000 Value and S&P 500.
In its third-quarter investor letter, SCCM Value Equity Strategy highlighted Bristol-Myers Squibb Company (BMY). The stock closed at $45.79 per share on November 19, 2025, with a one-month return of 4.47%. Bristol-Myers Squibb Company (BMY) has a market capitalization of $93.217 billion and experienced a 21.36% loss over the last 52 weeks.
Regarding Bristol-Myers Squibb Company (BMY), SCCM Value Equity Strategy stated that the stock selection within the Health Care sector impacted relative performance. Bristol-Myers Squibb Company (BMY) reported results that beat expectations but lowered EPS guidance due to R&D charges and loss-of-exclusivity pressures. Management aims to stabilize performance through realignment, cost discipline, and pipeline advancement.
Bristol-Myers Squibb Company (BMY) is not among the 30 most popular stocks among hedge funds. 67 hedge fund portfolios held Bristol-Myers Squibb Company (BMY) at the end of the second quarter. While Bristol-Myers Squibb Company (BMY) has investment potential, certain AI stocks offer greater upside potential and less downside risk. Investors seeking undervalued AI stocks can explore a free report on the best short-term AI stock.

Read more at Yahoo Finance: Bristol Myers Squibb Company (BMY) Slipped due to Lowered EPS Guidance